An article published last week on FierceBiotech described Russia's current biotech focus and the opportunities this may hold for U.S. companies. Over the past year or so, Russia has been increasingly focused on biotechnology companies as a way to diversify its $1.9 trillion economy. In particular, Russia's OAO Rusnano (formerly the state-owned Russion Corporation of Nanotechnologies, which was transitioned into Rusnano in President Vladimir Putin's second term) has purchased stakes in R&D companies from Europe, Israel, and the U.S. Such investments often require the transfer of technologies to Russia or are accompanied by the establishment of Russian-based laboratories, scientists, and patent rights, as noted in an article from BloombergBusinessweek.